G. O'neill

发表

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study

David H. Miller, D. MacManus, L. Kappos, 2012, Multiple sclerosis.

The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction

M. Duddy, M. Tintoré, A. Uccelli, 2016, Patient preference and adherence.

Neuroprotective agents for clinical trials in ALS

R. Conwit, L. Bruijn, B. Traynor, 2006, Neurology.

Acquired Disorders of the Neuromuscular Junction

G. O'neill, 2006, International anesthesiology clinics.

Comparison of Disease Activity in SPMS and PPMS in the Context of Multicenter Clinical Trials

Yong-Cheng Wang, D. Cadavid, G. O'neill, 2012, PloS one.

Chapter 82 – Tangier Disease and Neuropathy

M. Freeman, G. O'neill, 2005 .

First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica

P. Rolan, E. Aycardi, G. O'neill, 2015, PloS one.

Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes

P. Andersen, E. Pioro, W. Seltzer, 2003 .

Case records of the Massachusetts General Hospital. Case 22-2006--a 77-year-old man with a rapidly progressive gait disorder.

A. Stemmer-Rachamimov, R. Ackerman, R. Gonzalez, 2006, The New England journal of medicine.

Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis

Robert H. Brown, P. Andersen, E. Pioro, 2003 .

Neuroprotective agents for clinical trials in ALS: a systematic assessment.

R. Conwit, L. Bruijn, B. Traynor, 2006, Neurology.

[Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis].

D. Cadavid, G. O'neill, Yongqiang Tang, 2010, Revista de neurologia.

Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes.

Robert H. Brown, P. Andersen, E. Pioro, 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Toward more efficient clinical trials for amyotrophic lateral sclerosis

B. Levin, D. Schoenfeld, J. Glass, 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Ludwig Kappos, Ivan Rektor, David H. Miller, 2008, The Lancet.

Confirmation of linkage of type 1 hereditary sensory neuropathy to human chromosome 9q22

J. Haines, D. McKenna-Yasek, B. Hosler, 1999, Neurology.

Novel mutations in the gene encoding ATP-binding cassette 1 in four tangier disease kindreds.

L. M. Thurston, P. van Eerdewegh, M. Freeman, 2000, Journal of lipid research.

Seven-Tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy.

Elfar Adalsteinsson, Ellen Grant, Borjan Gagoski, 2008, Archives of neurology.

Inherited Disorders of the Neuromuscular Junction

G. O'neill, 2006, International anesthesiology clinics.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Xavier Montalban, James Sheridan, X. Montalban, 2010, The Lancet Neurology.

Refined mapping and characterization of the recessive familial amyotrophic lateral sclerosis locus (ALS2) on chromosome 2q33

J. Haines, H. Horvitz, M. Hamida, 1998, Neurogenetics.

An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers

D. Brooks, S. Papapetropoulos, P. He, 2010, Clinical neuropharmacology.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

X. Montalban, E. Radue, R. Gold, 2014, The Lancet Neurology.

ABCD1 translation–initiator mutation demonstrates genotype–phenotype correlation for AMN

G. O'neill, M. Aoki, Robert H. Brown, 2001, Neurology.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Gavin Giovannoni, Xavier Montalban, Ernst-Wilhelm Radue, 2013, The Lancet.

A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial (S01.005)

X. Montalban, E. Radue, R. Gold, 2012 .

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

D. Arnold, L. Kappos, S. Greenberg, 2015, The New England journal of medicine.

Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis

Limmroth, D. MacManus, L. Kappos, 2007 .

BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis

Limmroth, D. MacManus, L. Kappos, 2006 .

BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis

D. MacManus, L. Kappos, C. Polman, 2011, Journal of Neurology.

The efficacy of BG00012 in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2B study

Ludwig Kappos, Tarek A. Yousry, Dh Miller, 2008 .

Polyneuropathy in the mtDNA base pair 3243 point mutation

M. King, J. Poulton, J. Redmond, 1996, Neurology.

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

D. Arnold, L. Kappos, S. Greenberg, 2015, New England Journal of Medicine.

The Safety and Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis in the SELECTION Extension Study: Primary Results (S01.001)

X. Montalban, E. Radue, R. Gold, 2013, Neurology.

CD56bright Natural Killer Cell Expansion Predicts Response to Daclizumab HYP Treatment in RRMS: Results of the SELECT Trial (S31.004)

J. Sheridan, J. Elkins, G. O'neill, 2012 .